BioStock: Saniona achieves milestone with Boehringer Ingelheim

Saniona’s collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research milestone payment to Saniona. The partnership aims to address the cognitive impairments associated with schizophrenia, a critical aspect of the disorder that profoundly affects patients’ daily lives.

Read the article at biostock.se:

https://www.biostock.se/en/2024/10/saniona-achieves-milestone-with-boehringer-ingelheim/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/